Quture International, Inc. (OTCQB: TCLN) (PINKSHEETS: TCLN) and Quture, Inc. ("Quture") announced the commencement of the Demonstration Project for its QualOptima System at Jackson Memorial Hospital, University of Miami, on September 6, 2011. Today Quture announces the successful completion of the Demonstration of its new "transformative and disruptive" tool to enhance clinical performance to achieve optimal patient outcomes. The Investigational Review Board of the Miller School of Medicine, University of Miami, has now approved the protocol to use the product technology in an academic study. Furthermore, the product demonstration with InterSystems technology is now complete, moving the product significantly closer to commercial release.

Landon Feazell, CEO of Quture International, refers to his original statement of the significance of this accomplishment: "We are nearing announcement of our first newly enhanced product to connect true clinical quality with value. We are taking lessons learned from over 35 years of measuring performance manually and converting them into an electronic system that can provide real-time clinical knowledge and insight to doctors, nurses and hospitals as never before. Our years of developing clinical content and utilizing a new technology platform will finally achieve its potential. This is a significant milestone in the evolution of our now publicly traded company." He added: "Completion of this project, combined with the project nearing completion at Niagara Falls Memorial Medical Center, puts us very close to major announcements with InterSystems."

The Demonstration Project and now the academic study are designed by Keith A. Candiotti, M.D., Executive Vice-Chair & Chief Operating Officer, and Vice-Chair, Clinical Research, Department of Anesthesiology, Jackson Memorial Hospital and University of Miami Miller Medical School. The demonstration connects individual patient risk factors with evidence-based perioperative performance measures compared to patient outcomes. The impact of compliance on outcomes and costs associated with extended stays and complications in recovery and beyond for well-established performance measures in anesthesia connects clinical quality with outcomes and costs.

"It is truly remarkable to now lead this Company after years of development of intellectual property and clinical content. These transformative assets are converging on the remarkable InterSystems technology platform to derive clinical knowledge solutions," said Richard Fantozzi, M.D., CEO and Co-Chairman of Quture. "Following the InterSystems Global Summit just last week in Orlando and now with this achievement, the months ahead for Quture are very exciting to not only be part of, but lead. We believe we can solve the problems of disparate databases and silos of information that have limited our endeavors for over 35 years of clinical performance measurement in health care. This is a pivotal juncture in health care and its impact on the American economy and on the lives of patients and the professionals devoted to caring for them. We will be proud to introduce these new tools to accomplish our mission and bring new capability to the extensive new federal and national mandates and standards. These accomplishments are converging to pave the way for other anticipated business opportunities and reflect our current strategic plans to build long-term shareholder value."

QUTURE INTERNATIONAL, INC.

Quture International, Inc. is an emerging growth company positioned to become the leading clinical knowledge company in the world. The core competence of Quture is clinical performance enhancement to achieve optimal patient outcomes. Quture's brand is centered on the value proposition of trust, transparency and independence. As the free enterprise solution to improving health and health care while reducing costs, Quture is comprised of a subsidiary for the operations of its software technology solutions, plans for a "beyond data" consulting and knowledge applications company, as well as plans for a personalized, proactive, and predictive medicine company with a virtual community of members. These subsidiaries will all be affiliated with the Qx Medical Exchange, which the Company intends to become the largest medical and health exchange in the world. Quture International is a Nevada corporation currently trading under the symbol TCLN.

QUTURE, INC.

Quture, Inc. is the operations subsidiary of Quture International, Inc., positioned to become the international standard in health care performance, outcomes and analytics. Quture's transformational product QualOptima operates on the InterSystems technology platform, the leading software platform globally for health care. QualOptima is the transcendent healthcare analytics system for performance enhancement to achieve optimal patient outcomes. The analytics system measures performance against evidence-based optimal clinical processes of care. The clinical data repository of QualOptima, the Qualytx integrated aggregate clinical database, is planned to become the international common data platform for health and health care. Qualytx will then be capable of transforming personal health and health care through knowledge solutions founded on Quture's proprietary science of knowing what to measure, where that data resides in disparate databases, using the InterSystems technology to electronically abstract that data, and converting data to knowledge and actionable insight with its revolutionary and proprietary analytics system. As America transitions to payment for value and U.S. and international pressures converge to measure performance, Quture will navigate the future of global health and healthcare quality, patient safety and value.

This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. There is no assurance that a definitive agreement will be completed.

For Further Information Contact: Contact: Mele Telitz Director of Communications 303-204-4486 mele@quture.com Constellation Asset Advisors, Inc. Jens Dalsgaard President +1 (415) 524-8500